A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 29 May 2018
At a glance
- Drugs Dusigitumab (Primary) ; Aromatase inhibitors
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors MedImmune
- 26 Jan 2018 Planned End Date changed from 27 Oct 2017 to 8 Jun 2018.
- 26 Jan 2018 Planned primary completion date changed from 27 Oct 2017 to 8 Jun 2018.
- 10 Jun 2017 Biomarkers information updated